Associate Director, Regulatory Affairs- CMC & Device

Sr. Clinical Program Manager

Associate Director, Medical Writing

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Aruvant

Ascidian Therapeutics

Ascribe Bioscience

Akero Therapeutics is developing treatments for patients with serious metabolic diseases. Many metabolic diseases, such as non-alcoholic steatohepatitis (NASH), are marked by high unmet medical need. NASH is caused by excess storage of fat in the liver which causes liver inflammation and scarring. Akero is using a licensed engineered protein called efruxifermin (EFX) and developing it to treat the metabolic dysfunction that occurs in NASH patients. EFX is a differentiated Fc-FGF21 fusion protein that mimics native FGF21 to alleviate cellular stress and regulate metabolism. Building on positive Phase 2a results, EFX is now being used in Phase 2b clinical trials in pre-cirrhotic patients.

<p>Akero Therapeutics is developing treatments for patients with serious metabolic diseases. Many metabolic diseases, such as non-alcoholic steatohepatitis (NASH), are marked by high unmet medical need. NASH is caused by excess storage of fat in the liver which causes liver inflammation and scarring. Akero is using a licensed engineered protein called efruxifermin (EFX) and developing it to treat the metabolic dysfunction that occurs in NASH patients. EFX is a differentiated Fc-FGF21 fusion protein that mimics native FGF21 to alleviate cellular stress and regulate metabolism. Building on positive Phase 2a results, EFX is now being used in Phase 2b clinical trials in pre-cirrhotic patients.</p>


Find a biotech startup job.